Andreas Link
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andreas Link has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Michael Böhm
Universität des Saarlandes, Klinik für Innere Medizin III
6 shared publicationsM. Böhm
Universität des Saarlandes
4 shared publicationsJanine Pöss
Klinik für Innere Medizin III , Universitätsklinikum des Saarlandes , Homburg/Saar D-66421 , Germany
3 shared publicationsSimina Selejan
Klinik für Innere Medizin III , Universitätsklinikum des Saarlandes , Homburg/Saar D-66421 , Germany
3 shared publicationsAndrey Kazakov
From the Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany
2 shared publicationsFelix Walter
Klinik für Innere Medizin III , Universitätsklinikum des Saarlandes , D-66421 Homburg/Saar , Germany
2 shared publications
Latest Publications
- Open Access
- 1 January 2016
- Published by Elsevier in Annals of Intensive Care
- Vol. 6 (1) , 66
Runtime and aPTT predict venous thrombosis and thromboembolism in patients on extracorporeal membrane oxygenation: a retrospective analysis
- 1 January 2016
- Published by Elsevier in Annals of Intensive Care
- Vol. 6 (1) , 66
Open AccessRuntime and aPTT predict venous thrombosis and thromboembolism in patients on extracorporeal membrane oxygenation: a retrospective analysis
- Open Access
- 21 December 2014
- Published by Springer Nature in Critical Care
- Vol. 18 (6) , 713
Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial
Cardiogenic shock (CS) is the leading cause of death in patients hospitalized with acute myocardial infarction (AMI). Biomarkers might help in risk stratification and understanding of pathophysiology. Preliminary data suggests that patients with CS face a profound increase in the osteocyte-derived hormone fibroblast growth factor 23 (FGF-23), which acts as a negative regulator of serum phosphate levels. The present study aimed to assess the predictive role of FGF-23 for clinical outcome in a large cohort of CS patients with and without renal dysfunction. In the randomized Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial, 600 patients with CS complicating AMI were assigned to therapy with or without IABP. Our predefined biomarker substudy included 182 patients. Blood sampling was performed in a standardized procedure at three different time points (day 1 (day of admission), day 2 and day 3). Differences in outcome of patients with FGF-23 levels < and > median were compared by log-rank testing. Stepwise logistic regression modeling was performed to identify predictors of death at 30 days and Cox regression analysis for time to death during the first year. At all three time points, nonsurvivors had significantly higher FGF-23 levels compared to survivors (P <0.001 for all). Patients with FGF-23 levels above the median (395 RU/mL [interquartile range 102;2,395]) were characterized by an increased 30-day mortality and 1-year mortality. In multivariable analysis FGF-23 levels remained independent predictors for 30-day (odds ratio per 10log 1.80, 95% confidence interval (CI) 1.11 to 2.92; P = 0.02) and 1-year mortality (hazard ratio 1.50, 95% CI 1.11 to 2.04, P = 0.009). After stratifying the patients according to their baseline serum creatinine levels, the negative prognostic association of increased FGF-23 was only significant in those with serum creatinine greater than median. In CS, high levels of FGF-23 are independently related to a poor clinical outcome. However, this prognostic association appears only to apply in patients with impaired renal function. ClinicalTrials.gov NCT00491036 . Registered 22 June 2007.
- 21 December 2014
- Published by Springer Nature in Critical Care
- Vol. 18 (6) , 713
Open AccessFibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial
Cardiogenic shock (CS) is the leading cause of death in patients hospitalized with acute myocardial infarction (AMI). Biomarkers might help in risk stratification and understanding of pathophysiology. Preliminary data suggests that patients with CS face a profound increase in the osteocyte-derived hormone fibroblast growth factor 23 (FGF-23), which acts as a negative regulator of serum phosphate levels. The present study aimed to assess the predictive role of FGF-23 for clinical outcome in a large cohort of CS patients with and without renal dysfunction. In the randomized Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial, 600 patients with CS complicating AMI were assigned to therapy with or without IABP. Our predefined biomarker substudy included 182 patients. Blood sampling was performed in a standardized procedure at three different time points (day 1 (day of admission), day 2 and day 3). Differences in outcome of patients with FGF-23 levels < and > median were compared by log-rank testing. Stepwise logistic regression modeling was performed to identify predictors of death at 30 days and Cox regression analysis for time to death during the first year. At all three time points, nonsurvivors had significantly higher FGF-23 levels compared to survivors (P <0.001 for all). Patients with FGF-23 levels above the median (395 RU/mL [interquartile range 102;2,395]) were characterized by an increased 30-day mortality and 1-year mortality. In multivariable analysis FGF-23 levels remained independent predictors for 30-day (odds ratio per 10log 1.80, 95% confidence interval (CI) 1.11 to 2.92; P = 0.02) and 1-year mortality (hazard ratio 1.50, 95% CI 1.11 to 2.04, P = 0.009). After stratifying the patients according to their baseline serum creatinine levels, the negative prognostic association of increased FGF-23 was only significant in those with serum creatinine greater than median. In CS, high levels of FGF-23 are independently related to a poor clinical outcome. However, this prognostic association appears only to apply in patients with impaired renal function. ClinicalTrials.gov NCT00491036 . Registered 22 June 2007.
- 11 May 2014
- Published by Springer Nature in Die Innere Medizin
- Vol. 55 (6) , 655-662
Neues zur akuten Herzinsuffizienz
- 11 May 2014
- Published by Springer Nature in Die Innere Medizin
- Vol. 55 (6) , 655-662
Neues zur akuten Herzinsuffizienz
- 1 January 2014
- Published by Springer Nature
- p. 1-11
Akute Herzinsuffizienz
- 28 December 2013
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 103 (4) , 301-313
The Th17/Treg imbalance in patients with cardiogenic shock
Type 17 helper T (Th17) cells producing the proinflammatory signature cytokine interleukin (IL)-17 are conterregulated by regulatory T cells (Treg) producing anti-inflammatory cytokines like transforming growth factor (TGF)-β and interleukin-(IL)-10. An imbalance of the Th17/Treg-ratio toward Th17 cell subset was shown to be involved in plaque destabilization and acute myocardial infarction (AMI), while no data exist in infarction-related cardiogenic shock (CS). The objective of this study was to evaluate the role of Th17/Treg and their related cytokines in uncomplicated AMI and infarction-related CS. In an observational monocentric study, blood sample from age-matched healthy controls (HC, n = 20), patients with uncomplicated AMI (n = 20), patients with CS who survived for at least 28 days (CS-survivors, n = 20) and CS-non-survivors (n = 20) were analyzed. Circulating Th17 and Treg cell subsets and their intracellular cytokine expression were measured by flow cytometry and associated with circulating proinflammatory Th17-derived cytokines IL-6, IL-17 and their anti-inflammatory Treg-derived cytokines TGF-β and IL-10 measured by enzyme immunoassay. According to the severity of ACS, CS-non-survivors showed the highest levels of Th17 (p < 0.001) and the lowest levels of Treg cells (p < 0.001) favoring a Th17/Treg imbalance toward the proinflammatory Th17 response (p < 0.001). Changes of T cell subsets were also associated with a proinflammatory cytokine expression measured by increased IL-6 (p < 0.001) and IL-17 levels (p < 0.001) and decreased TGF-β (p < 0.001) and IL-10 levels (p = 0.057). For the Th17/Treg-ratio at admission, a cut-off point of >0.33 had a sensitivity of 90 % and a specificity of 80 % to determine 28-day mortality in CS (confirmed by ROC analysis, area under the curve: 0.88 ± 0.06, p < 0.001). Th17/Treg-ratio >0.33 was observed to be an independent predictor for 1-year mortality in CS confirmed by Cox proportional hazard analysis (hazard ratio (HR): 4.31; 95 % confidence interval (CI) 1.44–12.93; p = 0.009). The Th17/Treg imbalance toward a Th17 shift might represent a promising candidate as therapeutic target and risk indicator in cardiogenic shock.
- 28 December 2013
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 103 (4) , 301-313
The Th17/Treg imbalance in patients with cardiogenic shock
Type 17 helper T (Th17) cells producing the proinflammatory signature cytokine interleukin (IL)-17 are conterregulated by regulatory T cells (Treg) producing anti-inflammatory cytokines like transforming growth factor (TGF)-β and interleukin-(IL)-10. An imbalance of the Th17/Treg-ratio toward Th17 cell subset was shown to be involved in plaque destabilization and acute myocardial infarction (AMI), while no data exist in infarction-related cardiogenic shock (CS). The objective of this study was to evaluate the role of Th17/Treg and their related cytokines in uncomplicated AMI and infarction-related CS. In an observational monocentric study, blood sample from age-matched healthy controls (HC, n = 20), patients with uncomplicated AMI (n = 20), patients with CS who survived for at least 28 days (CS-survivors, n = 20) and CS-non-survivors (n = 20) were analyzed. Circulating Th17 and Treg cell subsets and their intracellular cytokine expression were measured by flow cytometry and associated with circulating proinflammatory Th17-derived cytokines IL-6, IL-17 and their anti-inflammatory Treg-derived cytokines TGF-β and IL-10 measured by enzyme immunoassay. According to the severity of ACS, CS-non-survivors showed the highest levels of Th17 (p < 0.001) and the lowest levels of Treg cells (p < 0.001) favoring a Th17/Treg imbalance toward the proinflammatory Th17 response (p < 0.001). Changes of T cell subsets were also associated with a proinflammatory cytokine expression measured by increased IL-6 (p < 0.001) and IL-17 levels (p < 0.001) and decreased TGF-β (p < 0.001) and IL-10 levels (p = 0.057). For the Th17/Treg-ratio at admission, a cut-off point of >0.33 had a sensitivity of 90 % and a specificity of 80 % to determine 28-day mortality in CS (confirmed by ROC analysis, area under the curve: 0.88 ± 0.06, p < 0.001). Th17/Treg-ratio >0.33 was observed to be an independent predictor for 1-year mortality in CS confirmed by Cox proportional hazard analysis (hazard ratio (HR): 4.31; 95 % confidence interval (CI) 1.44–12.93; p = 0.009). The Th17/Treg imbalance toward a Th17 shift might represent a promising candidate as therapeutic target and risk indicator in cardiogenic shock.
- 21 December 2013
- Published by Springer Nature in Medizinische Klinik - Intensivmedizin und Notfallmedizin
- Vol. 109 (1) , 69-70
Angiopoietin-2: Prognoseparameter im kardiogenen Schock
- 21 December 2013
- Published by Springer Nature in Medizinische Klinik - Intensivmedizin und Notfallmedizin
- Vol. 109 (1) , 69-70
Angiopoietin-2: Prognoseparameter im kardiogenen Schock
- Open Access
- 24 January 2013
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (22) , 1651-1662
Circulating angiopoietins and cardiovascular mortality in cardiogenic shock
Vascular integrity is disturbed in shock contributing to clinical appearance and serious outcomes. While angiopoietin (Ang)-1 protects from vascular inflammation and leakage, Ang-2 disrupts endothelial barrier function. The imbalance of Ang-1 and Ang-2, their association to haemodynamic deterioration, and their prognostic relevance are not known and, thus, were prospectively evaluated in patients with cardiogenic shock (CS) in this study. Plasma Ang-1 and Ang-2 were determined by the enzyme immunoassay in patients with CS (n = 96), uncomplicated acute myocardial infarction (AMI, n = 20) and age-matched healthy controls (HC, n = 20). Angiopoietin-2 was three-fold elevated in CS compared with HC (P < 0.001), remained elevated in non-survivors, and decreased in survivors (P < 0.001). In contrast, Ang-1 decreased up to 35-fold in CS (P < 0.001). Angiopoietin-1 was correlated and Ang-2 was inversely related to a cardiac power index and mixed venous oxygen saturation, respectively (P < 0.001 for all). To assess the prognostic relevance, two outcome variables were considered: the 28-day mortality and the survival time (follow-up time 1 year). For Ang-2 at admission a cut-off point of 2500 pg/mL had a sensitivity of 61% and a specificity of 80% to determine 28-day mortality in CS (confirmed by receiver operating characteristic analysis, area under the curve = 0.71 ± 0.06, P < 0.001). Angiopoietin-2 levels >2500 pg/mL at admission were observed to be an independent predictor for 1-year mortality in CS confirmed by Cox proportional hazard analysis [hazard ratio (HR) 2.11; 95% confidence interval (CI) 1.03–4.36; P = 0.042]. Circulating Angs are closely related to outcome and severity in CS. Angiopoietin-2 emerged as an independent predictor of 28-day and 1-year mortality in CS. Larger studies are required to define the cut-off and predictive values for Ang-2. Angiopoietins may be prognostic biomarkers for survival in CS and might represent a novel therapeutic target.
- 24 January 2013
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (22) , 1651-1662
Open AccessCirculating angiopoietins and cardiovascular mortality in cardiogenic shock
Vascular integrity is disturbed in shock contributing to clinical appearance and serious outcomes. While angiopoietin (Ang)-1 protects from vascular inflammation and leakage, Ang-2 disrupts endothelial barrier function. The imbalance of Ang-1 and Ang-2, their association to haemodynamic deterioration, and their prognostic relevance are not known and, thus, were prospectively evaluated in patients with cardiogenic shock (CS) in this study. Plasma Ang-1 and Ang-2 were determined by the enzyme immunoassay in patients with CS (n = 96), uncomplicated acute myocardial infarction (AMI, n = 20) and age-matched healthy controls (HC, n = 20). Angiopoietin-2 was three-fold elevated in CS compared with HC (P < 0.001), remained elevated in non-survivors, and decreased in survivors (P < 0.001). In contrast, Ang-1 decreased up to 35-fold in CS (P < 0.001). Angiopoietin-1 was correlated and Ang-2 was inversely related to a cardiac power index and mixed venous oxygen saturation, respectively (P < 0.001 for all). To assess the prognostic relevance, two outcome variables were considered: the 28-day mortality and the survival time (follow-up time 1 year). For Ang-2 at admission a cut-off point of 2500 pg/mL had a sensitivity of 61% and a specificity of 80% to determine 28-day mortality in CS (confirmed by receiver operating characteristic analysis, area under the curve = 0.71 ± 0.06, P < 0.001). Angiopoietin-2 levels >2500 pg/mL at admission were observed to be an independent predictor for 1-year mortality in CS confirmed by Cox proportional hazard analysis [hazard ratio (HR) 2.11; 95% confidence interval (CI) 1.03–4.36; P = 0.042]. Circulating Angs are closely related to outcome and severity in CS. Angiopoietin-2 emerged as an independent predictor of 28-day and 1-year mortality in CS. Larger studies are required to define the cut-off and predictive values for Ang-2. Angiopoietins may be prognostic biomarkers for survival in CS and might represent a novel therapeutic target.
- 12 September 2012
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 137 (38) , 1853-1856
21-jährige Patientin mit Reye-Syndrom nach grippalem Infekt
Anamnese und klinischer Befund: Eine 21-jährige Patientin wurde wegen zunehmender Vigilanzminderung stationär aufgenommen. Anfangs standen agitiert-delirante Symptome, später Somnolenz und Sopor im Vordergrund. Vorausgegangen war ein grippaler Infekt mit Fieber, Kopfschmerzen, Übelkeit und Erbrechen, der über mehrere Tage mit Acetylsalicylsäure behandelt worden war. Vorerkrankungen waren nicht bekannt. Untersuchungen: Die körperliche und klinisch-neurologischen Untersuchungen ergaben außer der Vigilanzminderung keinen auffälligen Befund. Das EEG zeigte mittelschwere Allgemeinveränderungen. Die kranielle MR-Tomographie und die Liquorpunktion waren unauffällig. Laborchemisch zeigte sich ein deutlicher Anstieg der Transaminasen sowie eine Hyperammonämie. Das toxikologische Screening war unauffällig. Therapie und Verlauf: Es wurde die Diagnose einer hepatischen Enzephalopathie infolge akuten Leberversagens gestellt und sofort eine Ammoniakdetoxikation mit Laktulose eingeleitet. Die transjuguläre Leberbiopsie ergab den Befund einer massiven Leberverfettung, deren Ursache weder serologisch noch histologisch geklärt werden konnte. Bei progredienter Vigilanzminderung wurde die Patientin intubiert und invasiv beatmet. Trotz raschen Absinkens des Ammoniak-Spiegels kam es zu einer weiteren neurologischen Verschlechterung. Im Kontroll-CCT zeigte sich ein Hirnödem mit Zeichen einer beginnenden Einklemmung. Eine Hirnödemtherapie wurde eingeleitet. Die Patientin starb infolge eines sekundären Hirnödems bei hepatischer Enzephalopathie. Folgerung: Bei Symptomen einer hepatischen Enzephalopathie bei akuter fettiger Leberdegeneration nach einem grippalen Infekt sowie der fakultativen Einnahme von Acetylsalicylsäure muss nach Ausschluss häufiger Ursachen eines akuten Leberversagens differenzialdiagnostisch das seltene Reye-Syndrom diskutiert werden. History and admission findings: A 21-year old woman was referred to the hospital because of progressively deteriorating consciousness. Initially agitation and irritability, later confusion and delirium predominated. Previously influenza with high temperature, headache and vomiting had occurred and been treated with acetylsalicylic acid for some days. Non preliminary diseases were reported. Clinical investigation: Besides of the deterioration in consciousness no clinical or neurological abnormalities were found. Electroencephalography demonstrated general abnormalities of medium range. Cranial magnetic resonance imaging and liquor investigations showed no pathological findings. In laboratory tests a marked increase of transaminases and ammonia were found. The toxicological screening was normal. Treatment and course: A hepatic encephalopathy due to acute hepatic failure was diagnosed and a detoxication of ammonemia with lactulose was started immediately. Transjugular liver biopsy showed a marked fattening of liver tissue without serological or histological findings for a reason. Because of progressive deterioration in consciousness mechanical ventilation became necessary. Despite of a rapid decline of ammonium serum levels further neurological deterioration occurred. Cranial computed tomography showed oedema of the cerebrum with beginning cerebral occlusion. Despite immediate therapy of cerebral oedema the patient died because of secondary cerebral oedema in hepatic encephalopathy. Conclusion: Reye‘s syndrome is an acute illness characterized by hepatic encephalopathy and fatty degeneration of the liver. It often occurs after viral infections. After a viral infection that was eventually treated with acetylsalicylic acid Reye‘s syndrome has to be discussed after exclusion of common causes of hepatic failure.
- 12 September 2012
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 137 (38) , 1853-1856
21-jährige Patientin mit Reye-Syndrom nach grippalem Infekt
Anamnese und klinischer Befund: Eine 21-jährige Patientin wurde wegen zunehmender Vigilanzminderung stationär aufgenommen. Anfangs standen agitiert-delirante Symptome, später Somnolenz und Sopor im Vordergrund. Vorausgegangen war ein grippaler Infekt mit Fieber, Kopfschmerzen, Übelkeit und Erbrechen, der über mehrere Tage mit Acetylsalicylsäure behandelt worden war. Vorerkrankungen waren nicht bekannt. Untersuchungen: Die körperliche und klinisch-neurologischen Untersuchungen ergaben außer der Vigilanzminderung keinen auffälligen Befund. Das EEG zeigte mittelschwere Allgemeinveränderungen. Die kranielle MR-Tomographie und die Liquorpunktion waren unauffällig. Laborchemisch zeigte sich ein deutlicher Anstieg der Transaminasen sowie eine Hyperammonämie. Das toxikologische Screening war unauffällig. Therapie und Verlauf: Es wurde die Diagnose einer hepatischen Enzephalopathie infolge akuten Leberversagens gestellt und sofort eine Ammoniakdetoxikation mit Laktulose eingeleitet. Die transjuguläre Leberbiopsie ergab den Befund einer massiven Leberverfettung, deren Ursache weder serologisch noch histologisch geklärt werden konnte. Bei progredienter Vigilanzminderung wurde die Patientin intubiert und invasiv beatmet. Trotz raschen Absinkens des Ammoniak-Spiegels kam es zu einer weiteren neurologischen Verschlechterung. Im Kontroll-CCT zeigte sich ein Hirnödem mit Zeichen einer beginnenden Einklemmung. Eine Hirnödemtherapie wurde eingeleitet. Die Patientin starb infolge eines sekundären Hirnödems bei hepatischer Enzephalopathie. Folgerung: Bei Symptomen einer hepatischen Enzephalopathie bei akuter fettiger Leberdegeneration nach einem grippalen Infekt sowie der fakultativen Einnahme von Acetylsalicylsäure muss nach Ausschluss häufiger Ursachen eines akuten Leberversagens differenzialdiagnostisch das seltene Reye-Syndrom diskutiert werden. History and admission findings: A 21-year old woman was referred to the hospital because of progressively deteriorating consciousness. Initially agitation and irritability, later confusion and delirium predominated. Previously influenza with high temperature, headache and vomiting had occurred and been treated with acetylsalicylic acid for some days. Non preliminary diseases were reported. Clinical investigation: Besides of the deterioration in consciousness no clinical or neurological abnormalities were found. Electroencephalography demonstrated general abnormalities of medium range. Cranial magnetic resonance imaging and liquor investigations showed no pathological findings. In laboratory tests a marked increase of transaminases and ammonia were found. The toxicological screening was normal. Treatment and course: A hepatic encephalopathy due to acute hepatic failure was diagnosed and a detoxication of ammonemia with lactulose was started immediately. Transjugular liver biopsy showed a marked fattening of liver tissue without serological or histological findings for a reason. Because of progressive deterioration in consciousness mechanical ventilation became necessary. Despite of a rapid decline of ammonium serum levels further neurological deterioration occurred. Cranial computed tomography showed oedema of the cerebrum with beginning cerebral occlusion. Despite immediate therapy of cerebral oedema the patient died because of secondary cerebral oedema in hepatic encephalopathy. Conclusion: Reye‘s syndrome is an acute illness characterized by hepatic encephalopathy and fatty degeneration of the liver. It often occurs after viral infections. After a viral infection that was eventually treated with acetylsalicylic acid Reye‘s syndrome has to be discussed after exclusion of common causes of hepatic failure.
- Open Access
- 29 May 2012
- Published by Springer Nature in Critical Care
- Vol. 16 (3) , R97
Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients
Introduction: Regional citrate anticoagulation is safe, feasible and increasingly used in critically ill patients on continuous renal replacement therapy (CRRT). However, in patients with hepatic or multi-organ dysfunction, citrate accumulation may lead to an imbalance of calcium homeostasis. The study aimed at evaluating the incidence and prognostic relevance of an increased total to ionized calcium ratio (T/I Ca2+ ratio) and its association to hepatic dysfunction. Methods: We performed a prospective observational study on n = 208 critically ill patients with acute kidney injury (AKI) and necessity for CRRT with regional citrate anticoagulation (CRRT-citrate) between September 2009 and September 2011. Critical illness was estimated by Simplified Acute Physiology Score II; hepatic function was measured with indocyanine green plasma disappearance rate. After achieving a steady state of calcium homeostasis patients were classified into tertiles according to the T/I Ca2+ ratio (2+ ratio was determined as an independent predictor for 28-day mortality in critically ill patients with AKI on CRRT-citrate confirmed by receiver operating characteristics and multivariate analysis (Area under the curve 0.94 ± 0.02; p2+ ratio ≥2.4 independently predicted a 33.5-fold (p2+ ratio and the hepatic clearance (p2+ ratio is closely related to the clinical outcome and emerged as an independent predictor of 28-day mortality. Larger studies are required to define the cut-off and predictive value for the T/I Ca2+ ratio. This ratio is associated with hepatic and/or multi-organ dysfunction and therefore an important therapeutic target.
- 29 May 2012
- Published by Springer Nature in Critical Care
- Vol. 16 (3) , R97
Open AccessTotal-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients
Introduction: Regional citrate anticoagulation is safe, feasible and increasingly used in critically ill patients on continuous renal replacement therapy (CRRT). However, in patients with hepatic or multi-organ dysfunction, citrate accumulation may lead to an imbalance of calcium homeostasis. The study aimed at evaluating the incidence and prognostic relevance of an increased total to ionized calcium ratio (T/I Ca2+ ratio) and its association to hepatic dysfunction. Methods: We performed a prospective observational study on n = 208 critically ill patients with acute kidney injury (AKI) and necessity for CRRT with regional citrate anticoagulation (CRRT-citrate) between September 2009 and September 2011. Critical illness was estimated by Simplified Acute Physiology Score II; hepatic function was measured with indocyanine green plasma disappearance rate. After achieving a steady state of calcium homeostasis patients were classified into tertiles according to the T/I Ca2+ ratio (2+ ratio was determined as an independent predictor for 28-day mortality in critically ill patients with AKI on CRRT-citrate confirmed by receiver operating characteristics and multivariate analysis (Area under the curve 0.94 ± 0.02; p2+ ratio ≥2.4 independently predicted a 33.5-fold (p2+ ratio and the hepatic clearance (p2+ ratio is closely related to the clinical outcome and emerged as an independent predictor of 28-day mortality. Larger studies are required to define the cut-off and predictive value for the T/I Ca2+ ratio. This ratio is associated with hepatic and/or multi-organ dysfunction and therefore an important therapeutic target.
- 15 May 2012
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 137 (21) , 1126-1129
Medikamentöse Therapie der akuten Herzinsuffizienz: Update und Perspektiven
Die akute Herzinsuffizienz bedarf einer raschen Diagnose und wenn möglich einer kausalen Therapie, um die Entwicklung eines kardiogenen Schocks zu vermeiden. Die medikamentösen Therapieprinzipien zielen auf eine Abnahme von klinischen Stauungszeichen, eine Vor- und Nachlastsenkung, eine myokardiale Kontraktilitätsteigerung und die Durchbrechung der neurohumoralen Aktivierung. Dabei soll die klinische Symptomatik verbessert, das Auftreten von Endorganschäden verhindert sowie wenn möglich die kardiovaskuläre Ereignis-, Rehospitalisations- und Mortalitätsrate reduziert werden. Eine kombinierte diuretische und / oder vasodilatatorische Standardtherapie ist einer Monotherapie im Hinblick auf die Organprotektion überlegen. Positiv inotrope und vasoaktive Substanzen sollten nur bei Hypotonie mit Zeichen der Kreislaufzentralisation eingesetzt werden. Sie verbessern die Hämodynamik und die Organperfusion unter Inkaufnahme einer Übersterblichkeit durch proarrhythmogene Effekte. Daher sollten sie so niedrig wie möglich dosiert und so rasch wie möglich ausgeschlichen werden. Eine vorbestehende Beta-Blocker-Therapie sollte, sofern keine hämodynamische Instabilität besteht, fortgesetzt werden. Wichtig ist, dass alle herzinsuffizienten Patienten vor Entlassung erneut leitliniengetreu auf Beta-Blocker und ACE-Hemmer eingestellt werden, da dadurch Rehospitalisation und Mortalität gesenkt werden können. Von neuen medikamentösen Therapieansätzen ist zumindest eine Symptomverbesserung und im günstigsten Fall eine Reduktion von Rehospitalisation und Mortalität zu fordern. In acute decompensated heart failure rapid diagnosis and causal therapy are necessary to avoid cardiogenic shock. Treatment goals are to decrease congestion, afterload, and neurohormonal activation in order to improve hemodynamics and symptoms and, perhaps, reduce in-hospital events, re-hospitalizations, and mortality. A combined medical therapy of diuretics and / or vasodilators should be favoured in order to protect organs and to avoid toxicities of therapy such as hypotension, arrhythmias and renal dysfunction. Intravenous inotropes, such as dobutamine and milrinone, should be limited to hypotensive patients with evidence of poor tissue perfusion. They improve hemodynamics and organ perfusion but result in a higher mortality due to to proarrhythmogenic effects. Therefore, they should be given in lowest doses and should be withdrawn as early as possible. A preexisting therapy with betablockers should be continued if there is no hemodynamic instability. Before demission any patient should be on betablockers and ACE inhibitors according to national guidelines resulting in a decrease of re-hospitalization and mortality rates. New medical therapies should at least improve clinical symptoms and favourably reduce re-hospitalization and mortality rates
- 15 May 2012
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 137 (21) , 1126-1129
Medikamentöse Therapie der akuten Herzinsuffizienz: Update und Perspektiven
Die akute Herzinsuffizienz bedarf einer raschen Diagnose und wenn möglich einer kausalen Therapie, um die Entwicklung eines kardiogenen Schocks zu vermeiden. Die medikamentösen Therapieprinzipien zielen auf eine Abnahme von klinischen Stauungszeichen, eine Vor- und Nachlastsenkung, eine myokardiale Kontraktilitätsteigerung und die Durchbrechung der neurohumoralen Aktivierung. Dabei soll die klinische Symptomatik verbessert, das Auftreten von Endorganschäden verhindert sowie wenn möglich die kardiovaskuläre Ereignis-, Rehospitalisations- und Mortalitätsrate reduziert werden. Eine kombinierte diuretische und / oder vasodilatatorische Standardtherapie ist einer Monotherapie im Hinblick auf die Organprotektion überlegen. Positiv inotrope und vasoaktive Substanzen sollten nur bei Hypotonie mit Zeichen der Kreislaufzentralisation eingesetzt werden. Sie verbessern die Hämodynamik und die Organperfusion unter Inkaufnahme einer Übersterblichkeit durch proarrhythmogene Effekte. Daher sollten sie so niedrig wie möglich dosiert und so rasch wie möglich ausgeschlichen werden. Eine vorbestehende Beta-Blocker-Therapie sollte, sofern keine hämodynamische Instabilität besteht, fortgesetzt werden. Wichtig ist, dass alle herzinsuffizienten Patienten vor Entlassung erneut leitliniengetreu auf Beta-Blocker und ACE-Hemmer eingestellt werden, da dadurch Rehospitalisation und Mortalität gesenkt werden können. Von neuen medikamentösen Therapieansätzen ist zumindest eine Symptomverbesserung und im günstigsten Fall eine Reduktion von Rehospitalisation und Mortalität zu fordern. In acute decompensated heart failure rapid diagnosis and causal therapy are necessary to avoid cardiogenic shock. Treatment goals are to decrease congestion, afterload, and neurohormonal activation in order to improve hemodynamics and symptoms and, perhaps, reduce in-hospital events, re-hospitalizations, and mortality. A combined medical therapy of diuretics and / or vasodilators should be favoured in order to protect organs and to avoid toxicities of therapy such as hypotension, arrhythmias and renal dysfunction. Intravenous inotropes, such as dobutamine and milrinone, should be limited to hypotensive patients with evidence of poor tissue perfusion. They improve hemodynamics and organ perfusion but result in a higher mortality due to to proarrhythmogenic effects. Therefore, they should be given in lowest doses and should be withdrawn as early as possible. A preexisting therapy with betablockers should be continued if there is no hemodynamic instability. Before demission any patient should be on betablockers and ACE inhibitors according to national guidelines resulting in a decrease of re-hospitalization and mortality rates. New medical therapies should at least improve clinical symptoms and favourably reduce re-hospitalization and mortality rates